BioSenic SA Logo

BioSenic SA

BIOS | BR

Overview

Corporate Details

ISIN(s):
BE0970179827 (+1 more)
LEI:
549300HFIIMTOP1DFR76
Country:
Belgium
Address:
RUE GRANBONPRÉ 11, 1435 MONT-ST-GUIBERT
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

BioSenic SA is a biotechnology company specializing in the development of innovative therapies for unmet medical needs in immunology and tissue repair. The company's clinical pipeline is built upon two core technology platforms: a proprietary formulation of arsenic trioxide (ATO) for treating autoimmune diseases by targeting the source of the immune cascade, and an allogeneic cell therapy platform (ALLOB) focused on organ and function repair. BioSenic leverages its expertise in innate immunity and cell-based treatments to advance its clinical assets.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for BioSenic SA. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-29 18:00
ISS
BIOS_PR_EN_2025 08_29.pdf
French 213.4 KB
2025-06-10 07:30
Legal Proceedings Report
BIOS_PR_20250610_EN.pdf
English 329.1 KB
2025-06-10 07:30
Capital/Financing Update
BIOS_PR_20250610-FR.pdf
French 280.9 KB
2025-06-09 07:30
Capital/Financing Update
BIOS_PR_20250610_EN.pdf
English 329.1 KB
2025-06-09 07:30
Legal Proceedings Report
BIOS_PR_20250610-FR.pdf
French 280.9 KB
2025-03-31 07:00
Declaration of Voting Results & Voting Rights Announcements
BIOS_PR_2025_March_Denominator_EN.pdf
English 285.4 KB
2025-03-31 07:00
Declaration of Voting Results & Voting Rights Announcements
BIOS_PR_2025_mars_Denominator_FR.pdf
French 249.4 KB
2025-03-04 21:00
Legal Proceedings Report
BIOS_PR_20250304_EN.pdf
English 275.4 KB
2025-03-04 21:00
Legal Proceedings Report
BIOS_PR_20250304_FR.pdf
French 237.3 KB
2025-01-27 17:30
Declaration of Voting Results & Voting Rights Announcements
BIOS_PR_2025_January_Denominator_EN.pdf
English 287.5 KB
2025-01-27 17:30
Declaration of Voting Results & Voting Rights Announcements
BIOS_PR_2025_janvier_Denominator_FR.pdf
French 252.0 KB
2025-01-23 21:30
Declaration of Voting Results & Voting Rights Announcements
BIOS_PR_2024_December_Denominator_EN.pdf
English 288.4 KB
2025-01-23 21:30
Declaration of Voting Results & Voting Rights Announcements
BIOS_PR_2024_décembre_Denominator_FR.pdf
French 251.6 KB
2025-01-23 21:00
Declaration of Voting Results & Voting Rights Announcements
BIOS_PR_2025-01-23_Transparency Notification_CGE_EN.pdf
English 283.5 KB
2025-01-23 21:00
Major Shareholding Notification
BIOS_PR_2025-01-23_Transparency Notification_CGE_FR_.pdf
French 249.7 KB

Automate Your Workflow. Get a real-time feed of all BioSenic SA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for BioSenic SA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-08-16 Rieger Francois Board Sell 2,500,000 25,000.00 EUR
2024-08-06 Rieger Francois Board Sell 868,653 7,186.87 EUR
2024-08-05 POMI SCHNEITER VERONIQUE Board Sell 534,750 4,331.47 EUR
2024-08-02 POMI SCHNEITER VERONIQUE Board Sell 193,900 1,609.37 EUR
2024-08-01 Rieger Francois Board Sell 1,236,684 11,463.87 EUR
2024-08-01 POMI SCHNEITER VERONIQUE Board Sell 140,003 1,246.03 EUR
2024-07-31 POMI SCHNEITER VERONIQUE Board Sell 503,771 4,685.07 EUR
2024-07-30 POMI SCHNEITER VERONIQUE Board Sell 360,021 3,348.20 EUR
2024-07-29 POMI SCHNEITER VERONIQUE Board Sell 372,893 3,430.62 EUR
2024-07-24 POMI SCHNEITER VERONIQUE Board Sell 2,168,361 21,033.10 EUR

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN